Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Conditions
Brief summary
This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back (relapsed), or small cell cancer that arises from a site other than the lung (extrapulmonary). Drugs used in chemotherapy, such as topotecan hydrochloride, work by damaging the DNA (deoxyribonucleic acid) in tumor cells, causing those cells to die and the tumor to shrink. However, some tumor cells can become less affected by chemotherapy because they have ways to repair the damaged DNA. The addition of M6620 could help topotecan hydrochloride shrink the cancer and prevent it from returning by blocking enzymes needed for DNA repair.
Detailed description
PRIMARY OBJECTIVE: I. To determine if the combination of berzosertib (M6620) with topotecan hydrochloride (topotecan) will result in an improvement in progression-free survival (PFS) compared to topotecan alone in patients with relapsed small cell lung cancer (SCLC). SECONDARY OBJECTIVE: I. To determine the objective response rate (ORR) and overall survival (OS) with the combination of M6220 and topotecan in patients with relapsed SCLC and extrapulmonary small cell cancers. EXPLORATORY OBJECTIVES: I. To perform molecular profiling assays on malignant and normal tissues, including, but not limited to ribonucleic acid (RNA) sequencing (RNA-Seq): Ia. To assess expression of genes Schlafen family member 11 (SLFN11), MYC, and ataxia-telangiectasia mutated (ATM) among others. Ib. To identify potential predictive biomarkers of response to a combination of M6620 with topotecan. Ic. Identify mechanisms of drug sensitivity and resistance using deoxyribonucleic acid (DNA)- and RNA-based assessment platforms. II. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome. III. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the Early-Phase and Experimental Clinical Trials (EET) Biobank at Nationwide Children's Hospital. IV. To characterize circulating cell-free DNA (cfDNA) and circulating tumor cells in patients with relapsed SCLC and extrapulmonary small cell cancers. V. To identify potential predictive biomarkers of response to a combination of M6620 with topotecan in patients with extrapulmonary small cell cancers. OUTLINE: Patients are assigned to 1 of 2 cohorts. COHORT I: Patients with SCLC are randomized to 1 of 2 arms. ARM I: Participants receive topotecan hydrochloride intravenously (IV) over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants may crossover to Arm II at disease progression. Participants undergo a computed tomography (CT) scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. ARM II: Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5 and berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. COHORT II (Patients with extrapulmonary small cell cancer): Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5 and berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. After completion of study treatment, patients are followed up at 4 weeks and then every 12 weeks thereafter.
Interventions
DRUGBerzosertib
Given IV
PROCEDUREBiopsy Procedure
Undergo a tumor biopsy
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDUREComputed Tomography
Undergo a CT scan
DRUGTopotecan Hydrochloride
Given IV
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients enrolled to the primary cohort must have limited- or extensive-disease SCLC at diagnosis, with relapse at study entry with measurable disease at random assignment per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Both platinum-sensitive and platinum-resistant patients will be included * Patients with extrapulmonary small cell cancers (cancers with small cell morphology and arising outside the lung, such as small cell prostate, bladder, etc.) will be eligible for the exploratory cohort * Patients must be \>= 18 years of age because no dosing or adverse event data are currently available on the use of M6620 in combination with topotecan in patients \<18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Hemoglobin \>= 9.0 g/dL - patients may receive transfusion to meet the hemoglobin (Hb) eligibility * Absolute neutrophil count (ANC) \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin =\< 2 mg/dL * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3.0 x institutional upper limit of normal (ULN) * Creatinine =\< institutional ULN OR * Glomerular filtration rate (GFR) \>= 60 mL/min/1.73 m\^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m\^2 * Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are eligible as long as they are on effective anti-retroviral therapy with undetectable viral load within 6 months and there is no drug-drug interaction with M6220 * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * The effects of M6620 on the developing human fetus are unknown. For this reason and because DNA-damage response (DDR) inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of M6620 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of M6620 administration * Patients with treated brain metastases are eligible if they are symptomatically stable while off steroid therapy for a minimum of 21 days * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients with symptomatic brain metastasis are not eligible due to their extremely poor prognosis and since it is unclear whether the investigational agent penetrates the blood-brain barrier. However, subjects who have had treatment for their brain metastasis and are symptomatically stable while off steroid therapy for a minimum of 21 days may be enrolled * Patients who have received prior topotecan therapy * Patients who have had chemotherapy or radiotherapy within 3 weeks prior to enrollment. * Note: Patients who have had palliative radiotherapy may be included as long as they have recovered from any radiotherapy related adverse events (allow at least a week between radiotherapy completion and study treatment) * Patients who have not recovered from adverse events due to prior anti-cancer therapy except hair loss and peripheral neuropathy (i.e., have residual toxicities \> grade 1) * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 or topotecan used in study * M6620 is primarily metabolized by cytochrome P450 3A4 (CYP3A4); therefore, concomitant administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) or inducers of CYP3A4 (e.g., rifampin, phenytoin, carbamazepine, phenobarbital, St. John's wort) should be avoided. Patients requiring any medications or substances that are strong inhibitors or inducers of CYP3A during the course of the study are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or of which to minimize use. The Patient Drug Interactions Handout and Wallet Card should be provided to patients. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * Patients with uncontrolled intercurrent illness * Pregnant women are excluded from this study because M6620 as a DDR inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M6620, breastfeeding should be discontinued if the mother is treated with M6620. These potential risks may also apply to topotecan used in this study * Patients with high grade neuroendocrine cancers, but with no small cell morphology will not be eligible * Patients with psychiatric illness/social situations that would limit compliance with study requirements * Patients with Li-Fraumeni syndrome will not be eligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) Reported With 80% Confidence Interval | From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort. | The combination of M6620 with topotecan will be compared to topotecan alone in participants with relapsed small cell lung cancer (SCLC). Kaplan-Meier curves and a one-tailed log-rank test will be the primary analysis methods. PFS is defined as the duration of time from start of treatment to time of progression or death. whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, and/or the appearance of one or more new lesions. |
| Progression-free Survival (PFS) Reported With 95% Confidence Interval | From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort. | The combination of M6620 with topotecan will be compared to topotecan alone in participants with relapsed small cell lung cancer (SCLC). Kaplan-Meier curves and a one-tailed log-rank test will be the primary analysis methods. PFS is defined as the duration of time from start of treatment to time of progression or death. whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, and/or the appearance of one or more new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to 2 years | ORR is defined as percentage of participants who achieved either complete response (CR) or partial response (PR) as best response assessed using the revised Response Evaluation Criteria in Solid Tumors guideline (v 1.1). ORR percentage is calculated as the sum of the PR and CR rates, divided by the total number of participants who are evaluable for a response, multiplied by 100%. All participants included in the study must be assessed for response to treatment, even if there are major protocol treatment deviations or if they are ineligible. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the diameters of target lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive disease is at least a 20% increase in the sum of the diameters of target lesions. |
| Overall Survival (OS) Reported With 80% Confidence Interval | Up to 2 years for pulmonary cohort and up 31.5 for Exploratory Cohort. | OS is defined as time from randomization to death, regardless of cause. |
| Overall Survival (OS) Reported With 95% Confidence Interval | Up to 2 years for pulmonary cohort and up 31.5 for Exploratory Cohort | OS is defined as time from randomization to death, regardless of cause. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAnish Thomas
National Cancer Institute LAO
Participant flow
Pre-assignment details
104 participants were enrolled, and 82/104 participants were treated as shown in the Participant Flow table.
Participants by arm
| Arm | Count |
|---|---|
| Platinum Response - Sensitive: Topotecan Monotherapy Cohort I, Arm I (topotecan hydrochloride) Participants with pulmonary disease receive topotecan hydrochloride intravenously (IV) over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants may crossover to Arm II at disease progression. Participants undergo a computed tomography (CT) scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. | 10 |
| Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy Cohort I, Arm II (topotecan hydrochloride & Berzosertib (M6620) Participants with pulmonary disease receive topotecan hydrochloride intravenously (IV) over 30 minutes on days 1-5 and Berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a computed tomography (CT) scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. | 20 |
| Platinum Response - Sensitive: Enrolled But Not Treated Participants with pulmonary disease were enrolled but not treated. | 10 |
| Platinum Response - Resistant: Topotecan Monotherapy Arm I (topotecan hydrochloride) Participants with pulmonary disease receive topotecan hydrochloride intravenously (IV) over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants may crossover to Arm II at disease progression. Participants undergo a computed tomography (CT) scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. | 11 |
| Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy Arm II (topotecan hydrochloride & Berzosertib (M6620) Participants with pulmonary disease receive topotecan hydrochloride intravenously (IV) over 30 minutes on days 1-5 and Berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a computed tomography (CT) scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. | 23 |
| Platinum Response - Resistant: Enrolled But Not Treated Participants with pulmonary disease were enrolled but not treated. | 9 |
| Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy Arm II (topotecan hydrochloride & Berzosertib (M6620) Participants receive topotecan hydrochloride intravenously (IV) over 30 minutes on days 1-5 and Berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a computed tomography (CT) scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. | 18 |
| Exploratory Cohort: Enrolled But Not Treated Participants were enrolled but not treated. | 3 |
| Total | 104 |
Baseline characteristics
| Characteristic | Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | Platinum Response - Sensitive: Enrolled But Not Treated | Platinum Response - Resistant: Topotecan Monotherapy | Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | Platinum Response - Resistant: Enrolled But Not Treated | Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | Platinum Response - Sensitive: Topotecan Monotherapy | Exploratory Cohort: Enrolled But Not Treated | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 8 Participants | 4 Participants | 4 Participants | 8 Participants | 3 Participants | 7 Participants | 3 Participants | 2 Participants | 39 Participants |
| Age, Categorical Between 18 and 65 years | 12 Participants | 6 Participants | 7 Participants | 15 Participants | 6 Participants | 11 Participants | 7 Participants | 1 Participants | 65 Participants |
| Age, Continuous | 61.65 years STANDARD_DEVIATION 9.05 | 63 years STANDARD_DEVIATION 8.17 | 61.72 years STANDARD_DEVIATION 7 | 60.60 years STANDARD_DEVIATION 7.57 | 58.33 years STANDARD_DEVIATION 8.83 | 57.94 years STANDARD_DEVIATION 13.24 | 56 years STANDARD_DEVIATION 9.53 | 64.33 years STANDARD_DEVIATION 2.49 | 60.16 years STANDARD_DEVIATION 9.48 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 20 Participants | 10 Participants | 11 Participants | 22 Participants | 9 Participants | 18 Participants | 10 Participants | 3 Participants | 103 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants | 0 Participants | 2 Participants | 10 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) White | 15 Participants | 10 Participants | 11 Participants | 20 Participants | 7 Participants | 14 Participants | 10 Participants | 1 Participants | 88 Participants |
| Region of Enrollment United States | 20 participants | 10 participants | 11 participants | 23 participants | 9 participants | 18 participants | 10 participants | 3 participants | 104 participants |
| Sex: Female, Male Female | 7 Participants | 5 Participants | 5 Participants | 10 Participants | 3 Participants | 5 Participants | 6 Participants | 0 Participants | 41 Participants |
| Sex: Female, Male Male | 13 Participants | 5 Participants | 6 Participants | 13 Participants | 6 Participants | 13 Participants | 4 Participants | 3 Participants | 63 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 9 / 9 | 19 / 20 | 11 / 11 | 19 / 20 | 15 / 16 | 5 / 5 | 6 / 6 |
| other Total, other adverse events | 8 / 9 | 20 / 20 | 11 / 11 | 19 / 20 | 16 / 16 | 5 / 5 | 6 / 6 |
| serious Total, serious adverse events | 6 / 9 | 12 / 20 | 9 / 11 | 11 / 20 | 9 / 16 | 4 / 5 | 4 / 6 |
Outcome results
Primary
Progression-free Survival (PFS) Reported With 80% Confidence Interval
The combination of M6620 with topotecan will be compared to topotecan alone in participants with relapsed small cell lung cancer (SCLC). Kaplan-Meier curves and a one-tailed log-rank test will be the primary analysis methods. PFS is defined as the duration of time from start of treatment to time of progression or death. whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, and/or the appearance of one or more new lesions.
Time frame: From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort.
Population: Participants enrolled but not treated are not reported for this outcome measure. Six participants from the groups reported below were not evaluable for this outcome measure. Participants who have results reported were placed into categories per initial randomization. Exploratory cohort consists of participants with extrapulmonary disease and were not randomized to treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Platinum Response - Sensitive: Topotecan Monotherapy | Progression-free Survival (PFS) Reported With 80% Confidence Interval | 5.5 Months |
| Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | Progression-free Survival (PFS) Reported With 80% Confidence Interval | 4.4 Months |
| Platinum Response - Resistant: Topotecan Monotherapy | Progression-free Survival (PFS) Reported With 80% Confidence Interval | 2.1 Months |
| Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | Progression-free Survival (PFS) Reported With 80% Confidence Interval | 2.7 Months |
| Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | Progression-free Survival (PFS) Reported With 80% Confidence Interval | 1.5 Months |
Primary
Progression-free Survival (PFS) Reported With 95% Confidence Interval
The combination of M6620 with topotecan will be compared to topotecan alone in participants with relapsed small cell lung cancer (SCLC). Kaplan-Meier curves and a one-tailed log-rank test will be the primary analysis methods. PFS is defined as the duration of time from start of treatment to time of progression or death. whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, and/or the appearance of one or more new lesions.
Time frame: From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort.
Population: Participants enrolled but not treated are not reported for this outcome measure. Six participants from the groups reported below were not evaluable for this outcome measure. Participants who have results reported were placed into categories per initial randomization. Exploratory cohort consists of participants with extrapulmonary disease and were not randomized to treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Platinum Response - Sensitive: Topotecan Monotherapy | Progression-free Survival (PFS) Reported With 95% Confidence Interval | 5.5 Months |
| Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | Progression-free Survival (PFS) Reported With 95% Confidence Interval | 4.4 Months |
| Platinum Response - Resistant: Topotecan Monotherapy | Progression-free Survival (PFS) Reported With 95% Confidence Interval | 2.1 Months |
| Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | Progression-free Survival (PFS) Reported With 95% Confidence Interval | 2.7 Months |
| Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | Progression-free Survival (PFS) Reported With 95% Confidence Interval | 1.5 Months |
Secondary
Objective Response Rate (ORR)
ORR is defined as percentage of participants who achieved either complete response (CR) or partial response (PR) as best response assessed using the revised Response Evaluation Criteria in Solid Tumors guideline (v 1.1). ORR percentage is calculated as the sum of the PR and CR rates, divided by the total number of participants who are evaluable for a response, multiplied by 100%. All participants included in the study must be assessed for response to treatment, even if there are major protocol treatment deviations or if they are ineligible. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the diameters of target lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive disease is at least a 20% increase in the sum of the diameters of target lesions.
Time frame: Up to 2 years
Population: Participants enrolled but not treated are not reported for this outcome measure. Ten participants from the groups reported below were not evaluable for this outcome measure. Participants who have results reported were placed into categories per initial randomization. Exploratory cohort consists of participants with extrapulmonary disease and were not randomized to treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Platinum Response - Sensitive: Topotecan Monotherapy | Objective Response Rate (ORR) | Complete Response | 0 Percentage of participants |
| Platinum Response - Sensitive: Topotecan Monotherapy | Objective Response Rate (ORR) | Partial Response | 12.5 Percentage of participants |
| Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | Objective Response Rate (ORR) | Complete Response | 0 Percentage of participants |
| Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | Objective Response Rate (ORR) | Partial Response | 35.0 Percentage of participants |
| Platinum Response - Resistant: Topotecan Monotherapy | Objective Response Rate (ORR) | Complete Response | 0 Percentage of participants |
| Platinum Response - Resistant: Topotecan Monotherapy | Objective Response Rate (ORR) | Partial Response | 0 Percentage of participants |
| Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | Objective Response Rate (ORR) | Partial Response | 15.8 Percentage of participants |
| Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | Objective Response Rate (ORR) | Complete Response | 0 Percentage of participants |
| Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | Objective Response Rate (ORR) | Complete Response | 0 Percentage of participants |
| Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | Objective Response Rate (ORR) | Partial Response | 23.3 Percentage of participants |
Secondary
Overall Survival (OS) Reported With 80% Confidence Interval
OS is defined as time from randomization to death, regardless of cause.
Time frame: Up to 2 years for pulmonary cohort and up 31.5 for Exploratory Cohort.
Population: Participants enrolled but not treated are not reported for this outcome measure. Six participants from the groups reported below were not evaluable for this outcome measure. Participants who have results reported were placed into categories per initial randomization. Exploratory cohort consists of participants with extrapulmonary disease and were not randomized to treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Platinum Response - Sensitive: Topotecan Monotherapy | Overall Survival (OS) Reported With 80% Confidence Interval | 6.5 Months |
| Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | Overall Survival (OS) Reported With 80% Confidence Interval | 9.6 Months |
| Platinum Response - Resistant: Topotecan Monotherapy | Overall Survival (OS) Reported With 80% Confidence Interval | 4.6 Months |
| Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | Overall Survival (OS) Reported With 80% Confidence Interval | 6.1 Months |
| Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | Overall Survival (OS) Reported With 80% Confidence Interval | 6.7 Months |
Secondary
Overall Survival (OS) Reported With 95% Confidence Interval
OS is defined as time from randomization to death, regardless of cause.
Time frame: Up to 2 years for pulmonary cohort and up 31.5 for Exploratory Cohort
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Platinum Response - Sensitive: Topotecan Monotherapy | Overall Survival (OS) Reported With 95% Confidence Interval | 6.5 Months |
| Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | Overall Survival (OS) Reported With 95% Confidence Interval | 9.6 Months |
| Platinum Response - Resistant: Topotecan Monotherapy | Overall Survival (OS) Reported With 95% Confidence Interval | 4.6 Months |
| Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | Overall Survival (OS) Reported With 95% Confidence Interval | 6.1 Months |
| Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | Overall Survival (OS) Reported With 95% Confidence Interval | 6.7 Months |
Other Pre-specified
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, an average of 801.3 days.
Population: Participants enrolled but not treated are not reported for this outcome measure. Adverse events would not be monitored/assessed if the participant never received drug. Six participants (i.e., enrolled but not treated) from the groups reported below were not evaluable for this outcome measure. Participants who have results reported were placed into categories per initial randomization. Exploratory cohort consists of participants with extrapulmonary disease and were not randomized to treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Platinum Response - Sensitive: Topotecan Monotherapy | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 8 Participants |
| Platinum Response - Sensitive: Topotecan & M6620 (VX-970) Combination Therapy | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 20 Participants |
| Platinum Response - Resistant: Topotecan Monotherapy | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 11 Participants |
| Platinum Response - Resistant: Topotecan & M6620 (VX-970) Combination Therapy | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 19 Participants |
| Exploratory Cohort: Topotecan & M6620 (VX-970) Combination Therapy | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 16 Participants |